Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Across 2, phase 3 studies, fremanezumab provided significant effects on monthly migraine days, regardless of whether patients were obese or not.

Efficacy and Safety of Fremanezumab Consistent in Patients With Migraine and Obesity

Even when combining both adult and pediatric patients, diazepam nasal spray administered within 5 minutes of a seizure led to quicker seizure termination.

Faster Initiation of Diazepam Nasal Spray Associated With More Rapid Seizure Termination

Videos

The assistant professor of neurology at Harvard Medical School talked about integrative therapies that may offer promising alternatives to traditional treatments for aiding neurological conditions. [WATCH TIME: 5 minutes]

Integrative and Alternative Patient-Centered Therapies in Neurology: Carolyn Bernstein, MD

Kate Labiner, MD, a pediatric epileptologist at Child Neurology Consultants of Austin, talked about the potential of cenobamate in pediatric patients with refractory focal epilepsy who have failed multiple medications.

Analysis on the Efficacy of Cenobamate in Pediatric Patients With Refractory Epilepsy

Dermatology resident, University Hospitals.

A trio of experts from university hospitals discussed a study that aimed to uncover the prevalence and associations of limb swelling in patients with Dravet syndrome in hopes of improving care. [WATCH TIME: 5 minutes]

Investigating Limb Swelling in Patients With Dravet Syndrome: Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD

The executive vice president of research at National MS Society talked about the Dystel Prize which is presented at AAN to a recognized individual who promotes further advancements in understanding and treating MS. [WATCH TIME: 3 minutes]

Recognizing Excellence in Multiple Sclerosis Research, the Dystel Prize: Bruce Bebo, PhD

Director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital.

The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]

New Insights into BTK Inhibitors and MRI Techniques for Smoldering MS: Thomas F. Scott, MD

, has been with the team since September 2022. Follow her on Twitter 

The executive vice president and chief research officer of the Muscular Dystrophy Association shared her reaction to the recent FDA approval of givinostat for Duchenne muscular dystrophy.

NeuroVoices: Sharon Hesterlee, PhD, on Givinostat’s Approval for Duchenne Muscular Dystrophy, Future Prospects

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

Allegheny Health Network

Articles